Sinphar Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
May 12, 2022
Share
Sinphar Pharmaceutical Co.,Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was TWD 668.81 million compared to TWD 616.84 million a year ago. Net income was TWD 58.1 million compared to TWD 5.03 million a year ago. Basic earnings per share from continuing operations was TWD 0.35 compared to TWD 0.03 a year ago. Diluted earnings per share from continuing operations was TWD 0.35 compared to TWD 0.03 a year ago.
Sinphar Pharmaceutical Co., Ltd. is principally engaged in the research and development, manufacture and distribution of pharmaceuticals. The Company is also engaged in the sales of functional food products. The Companyâs principal products include ointment, gel, cream, hard and soft capsules, sugar-coated tablets, film-coated tablets, suppositories, powders and granules, lozenges, soft candies, oral and topical liquid medicines, injections, dry medicated powers, functional food products, medical equipment and cosmetics. The Company mainly sells its products to hospitals, drug stores, clinics, dealers and distributors. Its primary markets are located in Taiwan and overseas countries.